Market Access Europe: It's Not Just About Price
“May you live in interesting times.”
Considered a curse by some, the saying could also be a blessing—especially when it comes to the evolving world of market access in Europe.
Given its complex geo-political situation, position in the global economy and number of voices to be heard, market access in Europe is both an environment of great hurdles—and great potential. While price and cost containment are major factors tackled by administrations and the pharmaceutical industry alike, it is only part of the story.
The rest of the tale is as multi-faceted as the region itself. National reimbursement policies that vary widely from country to country, payer restrictions and health care legislation have created an environment that can no longer focus solely on price. The result is a growing awareness in the industry of the importance of developing strategies that prepare the market, ensure there are no hidden payer issues and which pre-empt stakeholder concerns.
In Market Access Europe: It’s Not Just About Price, FirstWord casts a critical eye on the rapidly changing European environment to consider the key drivers and barriers to market access. The wide-ranging report addresses all major areas of market access in Europe, from value demonstration and partnership to price reference issues, the importance of communicating value and pan-European versus local approaches. The study includes interviews and access to some of the most senior and well-respected industry figures from PharmaPrice International, Novartis, Janssen and Axon Communications, amongst others. Concisely written, the report offers the industry discussions of major trends, insight into the pros and cons of specific approaches and most importantly of all, a thorough overview of the current state of the environment.
Scope
The report includes:
Considered a curse by some, the saying could also be a blessing—especially when it comes to the evolving world of market access in Europe.
Given its complex geo-political situation, position in the global economy and number of voices to be heard, market access in Europe is both an environment of great hurdles—and great potential. While price and cost containment are major factors tackled by administrations and the pharmaceutical industry alike, it is only part of the story.
The rest of the tale is as multi-faceted as the region itself. National reimbursement policies that vary widely from country to country, payer restrictions and health care legislation have created an environment that can no longer focus solely on price. The result is a growing awareness in the industry of the importance of developing strategies that prepare the market, ensure there are no hidden payer issues and which pre-empt stakeholder concerns.
In Market Access Europe: It’s Not Just About Price, FirstWord casts a critical eye on the rapidly changing European environment to consider the key drivers and barriers to market access. The wide-ranging report addresses all major areas of market access in Europe, from value demonstration and partnership to price reference issues, the importance of communicating value and pan-European versus local approaches. The study includes interviews and access to some of the most senior and well-respected industry figures from PharmaPrice International, Novartis, Janssen and Axon Communications, amongst others. Concisely written, the report offers the industry discussions of major trends, insight into the pros and cons of specific approaches and most importantly of all, a thorough overview of the current state of the environment.
Scope
The report includes:
- A full report on every aspect of market access in Europe
- Insight into the pros and cons of specific approaches
- Expert opinion on all major areas of concern in market access in Europe
- Detailed discussion of price and cost containment issues with a focus on value demonstration and partnership
- Case studies that highlight successful approaches
- Overview diagrams and up-to-date statistics to illustrate the scope of changes to the market
- Several key academic and industry references for further reading and detail
EXECUTIVE SUMMARY
THE EVOLUTION OF MARKET ACCESS
WHAT IS MARKET ACCESS?
PHARMACEUTICAL COMPANY ALIGNMENT TO THE EXTERNAL ENVIRONMENT
DEMONSTRATING AND COMMUNICATING VALUE
REGIONAL DIFFERENCES AND CHALLENGES
Expenditure on pharmaceuticals
Drug utilization
Approaches to price control
Fixed pricing
Cost effectiveness/cost benefit analysis/measurement
Profit caps, rebates and reductions
Reference pricing
MARKET ACCESS DYNAMICS
Patient- versus product-centric approaches to market access
The industry view
Patient and provider view
Pan-European vs. local approaches
Healthcare systems view
Pharmaceutical industry view
KEY MARKET ACCESS CHALLENGES AND OPPORTUNITIES
HTA: the challenges and the future
Efforts to create a European approach to HTA
Most believe that HTA should be driven by national needs
Pricing & reimbursement
Price controls
International reference pricing
Price interdependencies between countries
Value Based Pricing: A new level of pricing sophistication
Therapeutic/internal reference pricing and therapeutic substitution
Parallel imports
Risk share schemes
Disease management
Where can industry partner?
Value: Balancing the short term and the long term
Generic substitution
Generic-drug companies position in new drug development
Time for a new partnership model?
CRITICAL CONSIDERATIONS FOR APPROACHES TO MARKET ACCESS
Societal expectations
Government policies
Patient engagement
Payer engagement
Prescriber engagement
Long term partnerships between healthcare providers and industry are the way forward
CHALLENGES FOR INDUSTRY AND GOVERNMENTS
Continued innovation
Generic erosion of brands, new generics biosimilars
THE NEED FOR AN HOLISTIC APPROACH BY THE PHARMACEUTICAL INDUSTRY
LOOKING AHEAD: LINKING PRICE AND VALUE THROUGH PARTNERSHIP AND OUTCOMES
Partnership
Value based pricing methodologies
Patient-reported outcomes?demonstrating value well beyond price
THE EVOLUTION OF MARKET ACCESS
WHAT IS MARKET ACCESS?
PHARMACEUTICAL COMPANY ALIGNMENT TO THE EXTERNAL ENVIRONMENT
DEMONSTRATING AND COMMUNICATING VALUE
REGIONAL DIFFERENCES AND CHALLENGES
Expenditure on pharmaceuticals
Drug utilization
Approaches to price control
Fixed pricing
Cost effectiveness/cost benefit analysis/measurement
Profit caps, rebates and reductions
Reference pricing
MARKET ACCESS DYNAMICS
Patient- versus product-centric approaches to market access
The industry view
Patient and provider view
Pan-European vs. local approaches
Healthcare systems view
Pharmaceutical industry view
KEY MARKET ACCESS CHALLENGES AND OPPORTUNITIES
HTA: the challenges and the future
Efforts to create a European approach to HTA
Most believe that HTA should be driven by national needs
Pricing & reimbursement
Price controls
International reference pricing
Price interdependencies between countries
Value Based Pricing: A new level of pricing sophistication
Therapeutic/internal reference pricing and therapeutic substitution
Parallel imports
Risk share schemes
Disease management
Where can industry partner?
Value: Balancing the short term and the long term
Generic substitution
Generic-drug companies position in new drug development
Time for a new partnership model?
CRITICAL CONSIDERATIONS FOR APPROACHES TO MARKET ACCESS
Societal expectations
Government policies
Patient engagement
Payer engagement
Prescriber engagement
Long term partnerships between healthcare providers and industry are the way forward
CHALLENGES FOR INDUSTRY AND GOVERNMENTS
Continued innovation
Generic erosion of brands, new generics biosimilars
THE NEED FOR AN HOLISTIC APPROACH BY THE PHARMACEUTICAL INDUSTRY
LOOKING AHEAD: LINKING PRICE AND VALUE THROUGH PARTNERSHIP AND OUTCOMES
Partnership
Value based pricing methodologies
Patient-reported outcomes?demonstrating value well beyond price
